



In the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-51: Cancelled

52. (Currently Amended) An endostatin protein consisting of a fragment of a NC1 region of a collagen protein, wherein the fragment inhibits angiogenesis,

the endostatin protein having a molecular weight of approximately 18kDa as determined by non-reducing gel electrophoresis, wherein the N-terminal amino acid sequence is shown in SEQ ID NO:1 and wherein the protein is further characterized by its ability to specifically inhibit proliferating cultured endothelial cells.

53. (Previously Presented) The protein of Claim 52, wherein the protein is a fragment of a non-fibrillar collagen protein.

54. (Previously Presented) The protein of Claim 52, wherein the protein is a fragment of a collagen type XVIII protein.

55. (Previously Presented) The protein of Claim 52, wherein the protein is a fragment of a collagen type XV protein.

56. (Cancelled)

57. (Previously Presented) The protein of Claim 52, wherein the protein is produced recombinantly.

58. (Previously Presented) The protein of Claim 52, wherein the protein is naturally occurring.

59. (Previously Presented) The protein of Claim 52, wherein the protein is human.
60. (Previously Presented) The protein of Claim 52, wherein the protein inhibits angiogenesis *in vivo*.
61. (Previously Presented) The protein of Claim 52, wherein the protein inhibits angiogenesis *in vitro*.
62. (Cancelled)
63. (Currently Amended) A composition comprising, an endostatin protein combined with an angiostatin protein, wherein the endostatin protein consists of a fragment of a NC1 region of a collagen protein, wherein the angiostatin protein is a fragment of a kringle region of plasminogen and wherein the endostatin protein and the angiostatin protein are further characterized by their ability to inhibit angiogenesis,
the endostatin protein having a molecular weight of approximately 18kDa as determined by non-reducing gel electrophoresis, wherein the N-terminal amino acid sequence is shown in SEQ ID NO:1 and wherein the protein is further characterized by its ability to specifically inhibit proliferating cultured endothelial cells.
64. (Previously Presented) The composition of Claim 63, wherein the endostatin protein is a fragment of a non-fibrillar collagen protein.
65. (Previously Presented) The composition of Claim 63, wherein the endostatin protein is a fragment of a collagen type XVIII protein.
66. (Previously Presented) The composition of Claim 63, wherein the endostatin protein is a fragment of a collagen type XV protein.

67. (Cancelled)

68. (Previously Presented) The composition of Claim 63, wherein the endostatin protein and angiostatin protein are produced recombinantly.

69. (Previously Presented) The composition of Claim 63, wherein the endostatin protein and angiostatin protein are naturally occurring.

70. (Previously Presented) The composition of Claim 63, wherein the endostatin protein and angiostatin protein are human.

71. (Previously Presented) The composition of Claim 63, wherein the endostatin protein and angiostatin protein inhibit angiogenesis *in vivo*.

72. (Previously Presented) The composition of Claim 63, wherein the endostatin protein and angiostatin protein inhibit angiogenesis *in vitro*.

73. (Cancelled)